The tyrosine kinase receptor HER2 (erbB-2): from oncogenesis to adipogenesis.
Recent experimental evidences begin to support the notion that the proto-oncogene HER2 (erbB-2) might unexpectedly function to modulate the adipogenic conversion of preadipocytes. Two opposing scenarios have been proposed, however, to explain the influence of HER2 on adipocyte differentiation. In one hand, down-modulation of HER2 expression and pharmacological reduction of HER2 activity have been related to enhanced adipocyte differentiation. On the contrary, an increased abundance in HER2 has been described in differentiated adipocytes compared with preadipocytes. Considering that expression and activity of the lipogenic enzyme Fatty Acid Synthase (FASN) become up-regulated during adipogenic conversion, we recently hypothesized that a "HER2 --> FASN axis" -a "lipogenic benefit" that has been shown to enhance cancer cell proliferation, survival, chemoresistance and metastasis in biologically aggressive subgroups of breast carcinomas-might also naturally work during the differentiation of preadipocytes. To definitely clarify if the discrepancy between the opposing theories for a role of HER2 during adipocyte differentiation related to the experimental approach utilized to compare the abundance of HER2 in undifferentiated and differentiated adipocytes (i.e., cell lysates containing equivalent protein content versus cell lysates generated from similar cell numbers), we here took advantage of a high content microscopy approach. Using an automated confocal imaging platform, we monitored the expression status of the adipogenic marker FASN and its timing relationship with HER2 not only in individual 3T3-L1 cells but further in whole cultures of 3T3-L1 preadipocytes undergoing adipogenic conversion. Our findings not only confirm a non-oncogenic role for HER2 in the process of adipose differentiation but further suggest that HER2 might represent a previously unrecognized target to manage obesity via the lipogenic enzyme FASN.
Vazquez-Martin
Alejandro
A
Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IdIBGi), Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalonia, Spain.
Ortega-Delgado
Francisco Jose
FJ
Fernandez-Real
Jose Manuel
JM
Menendez
Javier A
JA
D041721:3T3-L1 Cells; D017667:Adipocytes / Q000166:cytology* / Q000378:metabolism; D050156:Adipogenesis / Q000502:physiology*; D000818:Animals; D002454:Cell Differentiation; D064429:Fatty Acid Synthases / Q000378:metabolism; D051379:Mice; D018613:Microscopy, Confocal; D009369:Neoplasms / Q000201:enzymology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
D064429:Fatty Acid Synthases; D018719:Erb-b2 Receptor Tyrosine Kinases